CBP-201 is under clinical development by Suzhou Connect Biopharmaceuticals and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CBP-201’s likelihood of approval (LoA) and phase transition for Asthma took place on 12 May 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 12 May 2022 decreased CBP-201’s Phase Transition Success Rate (PTSR) for Eosinophilic Esophagitis.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CBP-201 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CBP-201 overview

CBP-201 is under development for the treatment of allergic inflammation such as asthma, atopic dermatitis, food allergy, eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD). The drug candidate is a human monoclonal IgG4 monoclonal antibody that binds to IL-4R alpha. It is administered as subcutaneous or intravenous injection. It was also under development for nasal polyps.

It was also under development for the treatment of chronic rhinosinusitis.

Suzhou Connect Biopharmaceuticals overview

Suzhou Connect Biopharmaceuticals (Connect Biopharmaceuticals) discovers and develops next-generation immune modulators for the treatment of autoimmune diseases and inflammation. The company’s pipeline Product portfolio includes CBP-307 is an orally-active small molecule used for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD); CBP-201 is an antibody for asthma and atopic dermatitis; and CBP-174 is a small molecule inhibitor for the treatment of chronic skin inflammation. It utilizes T cell modulation technology platform for developing their products. Connect Biopharmaceuticals serves in the therapeutic areas of inflammatory bowel disease, psoriasis, multiple sclerosis and other autoimmune diseases. The company seeks to collaborate with pharmaceutical companies to develop and commercialize their products both inside and outside China. Connect Biopharmaceuticals is headquartered in Taicang, Jiangsu, China.

Quick View CBP-201 LOA Data

Report Segments
  • Innovator
Drug Name
  • CBP-201
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Dermatology
  • Ear Nose Throat Disorders
  • Gastrointestinal
  • Immunology
  • Respiratory
Key Developers
  • Sponsor Company: Suzhou Connect Biopharmaceuticals
  • Originator: Suzhou Connect Biopharmaceuticals
Highest Development Stage
  • Phase III


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.